Call  +41 61 926 6040
Fax +41 61 926 6049
Toggle Nav
My Cart
Search
Advanced Search
Account
Settings
Toggle Nav

Innaxon

Curcumin (high purity) Lipodisq™ Sterile Solution

CHF 244.00
In stock
IAX-700-101-L0011 mlCHF 244.00
Call  +41 61 926 6040
Fax  +41 61 926 6049
Contact Us!
Loading...
More Information
Product Details
Synonyms BRN 2306965; CCRIS 3257; NSC 32982; NSC 687842; CI 75300; 1,7-bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione, diferuloylmethane, nano-Curcumin in a detergent-free nano-formulation made of styrene-maleic acid lipid particles (SMALP)
Product Type Chemical
Properties
Formula

C21H20O6
MW 368.4
CAS 458-37-7
RTECS MI5230000
Source/Host Chemicals Synthetic. Originally isolated from turmeric (Curcuma longa).
Purity Chemicals ≥95% (HPLC)
Purity Detail Free of demethoxy- and bis-demethoxycurcumin. Curcumin in Lipodisq does not contain any bioactive impurities (usually present in up to 40% in natural formulations of curcumin).
Appearance Orange clear aqueous solution.
Solubility Soluble in water, PBS, Tris and other physiological solutions as formulated in a proprietary, thermostable, aqueous lipid nanoparticulate formulation (Lipodisq).
Reconstitution Avoid the use of buffers with divalent ions such as Ca or Mg or pH <6.5 or >8.0, which can cause particle instability.
Formulation Liquid, detergent-free discoidal nano-formulation made of styrene-maleic acid lipid particles (SMALP), lecithin and sterile water.
Concentration 1mg/ml (0.1% w/vol) Curcumin in Lipodisq corresponds to 271.7uM solution.
Biological Activity

Discoidal nano-particles can incorporate hydrophobic, poorly water-soluble compounds, such as lipids, lipoproteins and glycolipids. - Cell culture tested (human macrophage cell line) (MTT). - Recommended starting dilution: 1:200 or higher. - Optimal working concentrations depend on the applications and need to be determined. - Published procedures using Lipodisq formulations (Curcumin and IAXO TLR4 antagonists) in vivo rodent models at 3-10mg/kg. Recommended route of administration is subcutaneous (s.c.) with oral or nasal application as a possible alternative, which needs to be optimized.
Declaration Manufactured by Innaxon.
Other Product Data

Note: This highly purified product is free of demethoxy- and bis-demethoxycurcumin and does not contain 30-40% bioactive impurities.

Click here for Original Manufacturer Product Datasheet: Our product description may differ slightly from the original manufacturers product datasheet.


Lipodisq™ technology is covered by one or more of the following patents owned by Malvern Cosmeceutics Limited: AU2006253886, CA2611144, CN101184473B, EP1890675, GB2426703, IN261468, JP5142898, US8623414 and WO/2021/005340A1 pending. The purchaser is licensed under those patents to use these assemblies for the purpose of research and development only, but not for the purpose of delivery of agents for clinical use to humans or veterinary use to animals for therapeutic, diagnostic or prophylactic purposes, which uses are specifically prohibited.
InChi Key VFLDPWHFBUODDF-FCXRPNKRSA-N
Smiles COC1=CC(\C=C\C(=O)CC(=O)\C=C\C2=CC(OC)=C(O)C=C2)=CC=C1O
Shipping and Handling
Shipping AMBIENT
Short Term Storage +4°C
Long Term Storage +4°C
Handling Advice Keep sterile.
Protect from light.
Avoid skin and eye contact.
Use/Stability Stable for at least 1 year after receipt when stored at +4°C.
Documents
MSDS Download PDF
Product Specification Sheet
Datasheet Download PDF
Description
  • Curcumin (high purity) Lipodisq Sterile Solution is a ready-to-use nano-formulated aqueous solution.
  • Curcumin is a yellow pigment present in the spice turmeric (Curcuma longa) that has been associated with anti-oxidant, anti-inflammatory, anti-cancer, anti-viral and anti-bacterial activities [1-20]. However, curcumin shows poor absorption, biodistribution, metabolism and bioavailability. To increase the bioavailability, enhance circulation, improve permeability and resistance to metabolic processing several formulations of curcumin have been prepared which include nanoparticles, liposomes, micelles and phospholipid complexes [21-25].
  • Curcumin (high purity) Lipodisq is based on a nanoparticle (11-40nm) drug delivery system comprising a discoidal phospholipid bilayer membrane stabilized by a chaperone molecule annulus. Internal properties of the phospholipid membrane support the disposition and stabilization of drug molecule candidates and preserve the native conformation of membrane molecules. The resulting encapsulated actives are rendered water-soluble and specialized for intra-cellular penetration/delivery via endosomal uptake mechanisms. Lipodisq solutions show a good safety profile and are suitable for in vitro and in vivo investigations.
Product References
  1. Anticancer potential of curcumin: preclinical and clinical studies: B.B. Aggarwal, et al.; Anticancer Res. 23, 363 (2003) (Review)
  2. Multiple biological activities of curcumin: a short review: R.K. Maheshwari, et al.; Life Sci. 78, 2081 (2006) (Review)
  3. Antioxidant and anti-inflammatory properties of curcumin: V.P. Menon & A.R. Sudheer; Adv. Exp. Med. Biol. 595, 105 (2007) (Review)
  4. Antitumor, anti-invasion, and antimetastatic effects of curcumin: G. Kuttan, et al.; Adv. Exp. Med. Biol. 595, 173 (2007) (Review)
  5. Neuroprotective effects of curcumin: G.M. Cole, et al.; Adv. Exp. Med. Biol. 595, 197 (2007) (Review)
  6. Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases: B.B. Aggarwal & K.B. Harikumar; Int. J. Biochem. Cell Biol. 41, 40 (2009) (Review)
  7. Targeting inflammation-induced obesity and metabolic diseases by curcumin and other nutraceuticals: B.B. Aggarwal; Annu. Rev. Nutr. 30, 173 (2010) (Review)
  8. Development of curcumin as an epigenetic agent: S. Fu & R. Kurzrock; Cancer 116, 4670 (2010) (Review)
  9. The role of nutraceuticals in the regulation of Wnt and Hedgehog signaling in cancer: F.H. Sarkar, et al.; Cancer Metastasis Rev. 29, 383 (2010) (Review)
  10. Curcumin and obesity: evidence and mechanisms: L. Alappat & A.B. Awad; Nutr. Rev. 68, 729 (2010) (Review)
  11. Curcumin: a potential neuroprotective agent in Parkinson's disease: R.B. Mythri & M.M. Bharath; Curr. Pharm. Des. 18, 91 (2012) (Review)
  12. Targeting proteasomal pathways by dietary curcumin for cancer prevention and treatment: N. Hasima & B.B. Aggarwal; Curr. Med. Chem. 21, 1583 (2014)
  13. Curcumin as a MicroRNA Regulator in Cancer: A Review: A.A. Momtazi, et al.; Rev. Physiol. Biochem. Pharmacol. 171, 1 (2016) (Review)
  14. Curcumin: a modulator of inflammatory signaling pathways in the immune system: K.R. Kahkhaie, et al.; Inflammopharmacol. 27, 885 (2019) (Review)
  15. Antidiabetic Properties of Curcumin I: Evidence from In Vitro Studies: D.J.Den Hartogh, et al.; Nutrients 12, 118 (2020) (Review)
  16. Antidiabetic Properties of Curcumin II: Evidence from In Vivo Studies: D.J.Den Hartogh, et al.; Nutrients 12, 58 (2020) (Review)
  17. The Emerging Role of Curcumin in the Modulation of TLR-4 Signaling Pathway: Focus on Neuroprotective and Anti-Rheumatic Properties: M.A. Panaro, et al.; Int. J. Mol. Sci. 21, 2299 (2020) (Review)
  18. Curcumin as an Antiviral Agent: M.R. Jennings & R.J. Parks; Viruses 12, 1242 (2020) (Review)
  19. COVID-19: A Case for Inhibiting NLRP3 Inflammasome, Suppression of Inflammation with Curcumin? A.Saeedi-Boroujeni, et al.; Basic. Clin. Pharmacol. Toxicol. 128, 37 (2021) (Review)
  20. Curcumin and Biochemical Parameters in Metabolic-Associated Fatty Liver Disease (MAFLD): G. Rozanski, et al.; Nutrients 13, 2654 (2021)
  21. Formulation, characterization and evaluation of curcumin-loaded PLGA nanospheres for cancer therapy: A. Mukerjee & J.K. Vishwanatha; Anticancer Res. 29, 3867 (2009)
  22. Curcumin-decorated nanoliposomes with very high affinity for amyloid-beta1-42 peptide: S. Mourtas, et al.; Biomaterials 32, 1635 (2011)
  23. Novel lipid based oral formulation of curcumin: development and optimization by design of experiments approach: Y.B. Pawar, et al.; Int. J. Pharm. 436, 617 (2012)
  24. Purely aqueous PLGA nanoparticulate formulations of curcumin exhibit enhanced anticancer activity with dependence on the combination of the carrier: K.L. Nair, et al.; Int. J. Pharm. 425, 44 (2012)
  25. Anti-inflammatory activity of curcumin-loaded solid lipid nanoparticles in IL-1beta transgenic mice subjected to the lipopolysaccharide-induced sepsis: J. Wang, et al.; Biomaterials 53, 475 (2015)

General References for Lipodisq™ Technology:


  1. Responsive Hydrophobically Associating Polymers: A Review of Structure and Properties: S.R. Tonge & B.J. Tighe; Adv. Drug Deliv. Rev. 53, 109 (2001)
  2. Detergent-free formation and physico-chemical characterization of nanosized lipidpolymer complexes: Lipodisq; M.C. Orwick, et al.; Angew. Chem. 51, 4653 (2012)
  3. Physicochemical Characterization, Toxicity and In Vivo Biodistribution Studies of a Discoidal, Lipid-Based Drug Delivery Vehicle: Lipodisq Nanoparticles Containing Doxorubicin: M.L. Torgersen, et al.; J. Biomed. Nanotechnol. 16, 41 (2020)
  4. Applications of Synthetic Polymer Discoidal Lipid Nanoparticles to Biomedical Research: M. Tanaka; Chem. Pharm. Bull. 70, 507 (2022)
  5. Mechanisms of Formation, Structure, and Dynamics of Lipoprotein Discs Stabilized by Amphiphilic Copolymers: A Comprehensive Review: P.S. Orekhov, et al.; Nanomaterials 12, 361 (2022)
Related Products
© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.